Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute ... Sacramento Bee ... R343, an inhaled SYK inhibitor that has completed Phase 1 clinical trials for asthma; R333, a topical JAK/SYK inhibitor for discoid lupus; and R548, an oral JAK3 inhibitor for the treatment of transplant rejection and other immune disorders. |
